Publications
Efficacy and safety of a therapeutic humanized FSH-blocking antibody in obesity and Alzheimer's disease models. J Clin Invest. 10.1172/JCI182702
(2025) Efficacy and safety of a therapeutic humanized FSH-blocking antibody in obesity and Alzheimer's disease models. J Clin Invest. 10.1172/JCI182702
(2025) Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling. Proc Natl Acad Sci U S A. 122, e2501635122
(2025) Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling. Proc Natl Acad Sci U S A. 122, e2501635122
(2025) Exploring Alternative Zinc-Binding Groups in Histone Deacetylase (HDAC) Inhibitors Uncovers as a Potent Ethylhydrazide-Based HDAC Inhibitor with Chemosensitizing Properties. J Med Chem. 10.1021/acs.jmedchem.4c02373
(2025) Nitrous oxide production via enzymatic nitroxyl from the nitrifying archaeon . Proc Natl Acad Sci U S A. 122, e2416971122
(2025) A protective and broadly binding antibody class engages the influenza virus hemagglutinin head at its stem interface. mBio. 16, e0089225
(2025) Structural basis for complement receptor engagement and virus neutralization through Epstein-Barr virus gp350. Immunity. 58, 295-308.e5
(2025) Structures of TGF-β with betaglycan and signaling receptors reveal mechanisms of complex assembly and signaling.. Nat Commun. 16, 1778
(2025) A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins. J Med Chem. 68, 1092-1112
(2025) A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins. J Med Chem. 68, 1092-1112
(2025) A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins. J Med Chem. 68, 1092-1112
(2025) A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins. J Med Chem. 68, 1092-1112
(2025) Targeting transcription factors through an IMiD independent zinc finger domain. EMBO Mol Med. 17, 1393-1416
(2025) (2025)